"10.1371_journal.pone.0109420","plos one","2014-10-08T00:00:00Z","Hugues Charest; Florence Doualla-Bell; Régis Cantin; Donald G Murphy; Linda Lemieux; Bluma Brenner; Isabelle Hardy; Daniela Moisi; Ernest Lo; Jean-Guy Baril; Mark A Wainberg; Michel Roger; Cécile Tremblay","Laboratoire de santé publique du Québec/Institut national de santé publique du Québec, Sainte-Anne-de-Bellevue, Québec, Canada; Département de microbiologie, infectiologie et immunologie, Faculté de médecine, Université de Montréal, Montréal, Québec, Canada; Department of Medicine, Division of Experimental Medicine, McGill University, Montréal, Québec, Canada; McGill AIDS Center, Lady Davis Institute, Jewish General Hospital, McGill University, Montréal, Québec, Canada; Centre hospitalier de lUniversité de Montréal (CHUM), Montréal, Québec, Canada; Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada; Clinique du Quartier Latin, Montréal, Québec, Canada","Conceived and designed the experiments: HC FDB CT. Performed the experiments: HC IH DM BB MR. Analyzed the data: LL RC HC DGM EL. Contributed reagents/materials/analysis tools: HC RC LL EL. Contributed to the writing of the manuscript: HC FDB MAW JGB CT.","The authors have read the journals policy and have the following competing interests: JGB has served as an ad hoc advisor and has presented at various events sponsored by Abbott, Bristol-Myers Squibb, GlaxoSmithKline, ViiV Healthcare, Janssen, Merck Frosst and Gilead, and has received grants from these pharmaceutical companies. CT has served as an advisor and is a board member of Gilead, Merck and Tibotec, and has presented at various events sponsored by these pharmaceutical companies, in addition to Bristol-Myers Squibb and Abbott. JGB and CT are physicians treating HIV infected patients in their medical practice, and are active members of the provincial advisory committee mandated by the Ministry of Health for reviewing the clinical relevance of different molecular assays for the follow-up of individuals infected with HIV. Other authors (IT specialists and laboratory staff) have no interaction with patients. No pharmaceutical companies are mentioned in this manuscript. HC, FDB, LL, RC, DGM, IH, DM, BB, MR, EL, MAW have declared that no competing interests exist. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2014","10","Hugues Charest","HC",13,FALSE,3,5,5,NA,TRUE,TRUE,FALSE,0,NA,FALSE
